CL2020003220A1 - New protein with anti-inflammatory properties - Google Patents

New protein with anti-inflammatory properties

Info

Publication number
CL2020003220A1
CL2020003220A1 CL2020003220A CL2020003220A CL2020003220A1 CL 2020003220 A1 CL2020003220 A1 CL 2020003220A1 CL 2020003220 A CL2020003220 A CL 2020003220A CL 2020003220 A CL2020003220 A CL 2020003220A CL 2020003220 A1 CL2020003220 A1 CL 2020003220A1
Authority
CL
Chile
Prior art keywords
inflammatory properties
new protein
seq
prevention
isolated
Prior art date
Application number
CL2020003220A
Other languages
Spanish (es)
Inventor
Valerie Mary Corrigall
Gabriel Stavros Panayi
Original Assignee
Immune regulation ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1809703.0A external-priority patent/GB201809703D0/en
Priority claimed from US16/007,742 external-priority patent/US10858409B2/en
Application filed by Immune regulation ltd filed Critical Immune regulation ltd
Publication of CL2020003220A1 publication Critical patent/CL2020003220A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención proporciona una proteína aislada o recombinante que consiste en la secuencia de aminoácidos de acuerdo con la SEQ ID NO: 3 o SEQ ID: NO: 4 y su uso en la prevención o el tratamiento de una afección inflamatoria.The present invention provides an isolated or recombinant protein consisting of the amino acid sequence according to SEQ ID NO: 3 or SEQ ID: NO: 4 and its use in the prevention or treatment of an inflammatory condition.

CL2020003220A 2018-06-13 2020-12-11 New protein with anti-inflammatory properties CL2020003220A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1809703.0A GB201809703D0 (en) 2018-06-13 2018-06-13 Novel protein with anti-inflammatory properties
US16/007,742 US10858409B2 (en) 2018-06-13 2018-06-13 Protein with anti-inflammatory properties

Publications (1)

Publication Number Publication Date
CL2020003220A1 true CL2020003220A1 (en) 2021-10-01

Family

ID=66999851

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020003220A CL2020003220A1 (en) 2018-06-13 2020-12-11 New protein with anti-inflammatory properties

Country Status (14)

Country Link
EP (1) EP3807303A1 (en)
JP (1) JP2021528100A (en)
KR (1) KR20210039339A (en)
CN (1) CN112888704A (en)
AU (2) AU2019285831B2 (en)
BR (1) BR112020025398A2 (en)
CA (1) CA3103370A1 (en)
CL (1) CL2020003220A1 (en)
CO (1) CO2020016749A2 (en)
IL (1) IL279350A (en)
MX (1) MX2020013569A (en)
SG (1) SG11202012363XA (en)
WO (1) WO2019239126A1 (en)
ZA (1) ZA202100115B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023187422A1 (en) 2022-03-31 2023-10-05 Revolo Biotherapeutics Limited Compositions and their use in methods for treating intestinal inflammation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9822115D0 (en) * 1998-10-09 1998-12-02 King S College London Treatment of inflammatory disease
GB0106161D0 (en) 2001-03-13 2001-05-02 King S College London Immunomodulators
DE10127572A1 (en) * 2001-05-30 2002-12-05 Pathoarray Gmbh Tools for the diagnosis, molecular definition and therapy development of chronic inflammatory joint diseases
WO2006073446A2 (en) * 2004-04-28 2006-07-13 The Trustees Of The University Of Pennsylvania Peptide-mediated protein transduction into cells the hematopoietic lineage
EP1874331B1 (en) * 2005-04-19 2014-09-03 Kings College London Use of bip against bone loss and osteoporosis
EP2872644B1 (en) * 2012-07-12 2017-07-12 UAB Baltymas Generation of native recombinant secreted human endoplasmic reticulum chaperones by using their native signal sequences in yeast expression systems
US20140294902A1 (en) * 2013-04-02 2014-10-02 Protagonist Therapeutics, Inc. Novel a4b7 peptide antagonists
KR101731908B1 (en) * 2015-08-18 2017-05-11 서울대학교산학협력단 Autophagy stimulation using p62 ZZ domain binding compounds or arginylated BiP for the prevention or treatment of neurodegenerative disease

Also Published As

Publication number Publication date
ZA202100115B (en) 2022-07-27
CO2020016749A2 (en) 2021-04-08
KR20210039339A (en) 2021-04-09
CA3103370A1 (en) 2019-12-19
CN112888704A (en) 2021-06-01
AU2024200977A1 (en) 2024-03-07
BR112020025398A2 (en) 2021-04-06
MX2020013569A (en) 2021-05-27
WO2019239126A1 (en) 2019-12-19
AU2019285831B2 (en) 2023-11-16
JP2021528100A (en) 2021-10-21
AU2019285831A1 (en) 2021-01-28
EP3807303A1 (en) 2021-04-21
SG11202012363XA (en) 2021-01-28
IL279350A (en) 2021-01-31

Similar Documents

Publication Publication Date Title
CL2018003322A1 (en) Interleukin 23 receptor peptide inhibitors and their use to treat inflammatory diseases. (divisional application 201800128)
WO2018229236A3 (en) Compositions comprising bacterial strains
CY1121658T1 (en) PEPTIDES AND THEIR USE
NZ730865A (en) Peptides having anti-inflammatory properties
RS53505B1 (en) Oxyntomodulin peptide analogue
AR113422A2 (en) RECONSTITUTED SURFACTIVE AGENTS HAVING IMPROVED PROPERTIES
EA201990298A1 (en) METHODS AND COMPOSITIONS FOR CANCER TREATMENT
PE20220505A1 (en) TIGIT AND PD-1/TIGIT BINDING MOLECULES
CO2021017664A2 (en) peptides
EA202190310A1 (en) PROTEIN FOR INFLAMMATORY DISEASES
PE20151978A1 (en) NUTRITIONAL COMPOSITIONS CONTAINING A PEPTIDIC COMPONENT WITH ANT-INFLAMMATORY PROPERTIES AND USES OF THE SAME
BR112013013548B8 (en) ANTI-CANCER FUSION PROTEIN
JOP20200323A1 (en) Methods of manufacturing amino acid compositions
PE20170955A1 (en) NEW INSECT INHIBITOR PROTEINS
BR112018000660A2 (en) anti-inflammatory peptides and their use
MX2017006748A (en) Amino acid compositions for the treatment of symptoms of disease.
WO2019094938A3 (en) Methods and compositions for the treatment of wounds
AR075933A1 (en) POLYPEPTIDE AND IMMUNIZATION COMPOSITIONS CONTAINING GRAM POSITIVE POLYPEPTIDES AND METHODS OF USE
CO2017013404A2 (en) Variants of il-37
CL2020003220A1 (en) New protein with anti-inflammatory properties
AR102890A1 (en) POLYPEPTIDES THAT INCLUDE A SEQUENCE OF G3P AMINO ACIDS OF BACTERIOPHAGUS WITHOUT GLUCOSILATION SIGNAL
BR112013025975A2 (en) anticancer fusion protein
EA202092963A1 (en) NEW PROTEIN WITH ANTI-INFLAMMATORY PROPERTIES
ES2526109R2 (en) PEPTIDE AND PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT
MX2017013480A (en) Pharmaceutical composition for treating and/or preventing cancer.